Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversion

dc.contributor.author
Velasco, Iván
dc.contributor.author
Salazar, Patricia
dc.contributor.author
Ramos-Mejía, Verónica
dc.contributor.author
Castaño, Julio
dc.contributor.author
Giorgetti, Alessandra
dc.contributor.author
Romero Moya, Damià
dc.contributor.author
Menéndez Buján, Pablo
dc.date.issued
2021-04-20T09:36:15Z
dc.date.issued
2021-04-20T09:36:15Z
dc.date.issued
2014-11-01
dc.date.issued
2021-04-20T09:36:16Z
dc.identifier
1066-5099
dc.identifier
https://hdl.handle.net/2445/176401
dc.identifier
711116
dc.identifier
24989459
dc.description.abstract
Access to healthy or diseased human neural tissue is a daunting task and represents a barrierfor advancing our understanding about the cellular, genetic, and molecular mechanisms underly-ing neurogenesis and neurodegeneration. Reprogramming of somatic cells to pluripotency bytransient expression of transcription factors was achieved a few years ago. Induced pluripotentstem cells (iPSC) from both healthy individuals and patients suffering from debilitating, life-threatening neurological diseases have been differentiated into several specific neuronal sub-types. An alternative emerging approach is the direct conversion of somatic cells (i.e., fibro-blasts, blood cells, or glial cells) into neuron-like cells. However, to what extent neuronal directconversion of diseased somatic cells can be achieved remains an open question. Optimizationof current expansion and differentiation approaches is highly demanded to increase the differ-entiation efficiency of specific phenotypes of functional neurons from iPSCs or through somaticcell direct conversion. The realization of the full potential of iPSCs relies on the ability to pre-cisely modify specific genome sequences. Genome editing technologies including zinc fingernucleases, transcription activator-like effector nucleases, and clustered regularly interspacedshort palindromic repeat/CAS9 RNA-guided nucleases have progressed very fast over the lastyears. The combination of genome-editing strategies and patient-specific iPSC biology will offera unique platform for in vitro generation of diseased and corrected neural derivatives for per-sonalized therapies, disease modeling and drug screening.
dc.format
7 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
AlphaMed Press
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1002/stem.1782
dc.relation
Stem Cells, 2014, vol. 32, num. 11, p. 2811-2817
dc.relation
https://doi.org/10.1002/stem.1782
dc.rights
cc by (c) Velasco et al, 2014
dc.rights
http://creativecommons.org/licenses/by-cc-by/3.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Cèl·lules
dc.subject
Fisiologia
dc.subject
Enginyeria genètica
dc.subject
Citologia
dc.subject
Cells
dc.subject
Physiology
dc.subject
Genetic engineering
dc.subject
Cytology
dc.title
Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversion
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)